Theriva Biologics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
TOVX NYSE American 2834 therivabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Theriva Biologics, Inc.

Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer - May 27th, 2025 6:00 am
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - May 14th, 2025 6:40 am
Theriva Biologics: Q1 Earnings Snapshot - May 14th, 2025 6:22 am
Theriva Biologics Announces Closing of $7.5 Million Public Offering - May 8th, 2025 2:30 pm
Theriva Biologics Announces Pricing of $7.5 Million Public Offering - May 7th, 2025 7:17 am
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients - May 7th, 2025 5:00 am
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - Apr 10th, 2025 6:00 am
Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) - Mar 31st, 2025 6:00 am
Theriva™ Biologics to Present at the 2025 NeauxCancer Conference - Mar 19th, 2025 6:10 am
Q1 Virtual Investor Summit: On-Demand Presentations Now Live - Mar 18th, 2025 1:30 pm
Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results - Mar 6th, 2025 2:10 pm
Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual - Mar 5th, 2025 2:05 pm
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer - Dec 5th, 2024 6:00 am
Theriva Biologics: Q3 Earnings Snapshot - Nov 12th, 2024 6:23 am
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant - Oct 31st, 2024 2:05 pm
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - Oct 16th, 2024 6:00 am
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients - Oct 3rd, 2024 8:45 am
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - Oct 3rd, 2024 6:00 am
Theriva Biologics Announces Pricing of $2.5 Million Public Offering - Sep 26th, 2024 7:06 pm
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer - Sep 23rd, 2024 6:00 am